Gilead Sciences, Inc.
NASDAQGilead Sciences heads into the back half of May nursing a 3.3% weekly decline and a 5.2% one-month loss — a drift that an upgrade this morning from Maxim Group has not been enough to arrest. The freshest piece of analyst news landed at the open on May 20. Maxim moved GILD to Buy with a $165 target, pulling the consensus one step warmer. That follows Truist Securities…
Snapshot as of 22 Jun 2026
A new long-form analysis for GILD this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumGilead Sciences heads into the back half of May nursing a 3.3% weekly decline and a 5.2% one-month loss — a drift that an upgrade this morning from Maxim Group has not been enough to arrest. The freshest piece of…
Gilead Sciences reports Q1 2026 results today against a backdrop of broad analyst conviction — but a stock that has quietly drifted lower and a short interest position that has been building steadily through April. The…
Gilead Sciences walks into its Q1 2026 results — scheduled for after the close on April 30 — with a notable tension: short interest has risen sharply over the past month, yet the Street remains firmly bullish and a…
Short sellers have largely abandoned GILD ahead of today's earnings. Just 1.73% of the float is sold short, up slightly from March lows but still among the lowest in large-cap biotech. Short interest stands at 21.5…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GILD — free to start on ORTEX.
Sign up for free →Open GILD on ORTEX